Comparison of Sublingual Misoprostol and Intravenous Oxytocin in Active Management of the Third Stage of Labor

This study is not yet open for participant recruitment.
Verified June 2012 by Ain Shams University
Sponsor:
Collaborator:
Ain Shams University
Information provided by (Responsible Party):
Rasha Mohammed Mohammed Badawi, Ain Shams University
ClinicalTrials.gov Identifier:
NCT01612390
First received: June 2, 2012
Last updated: June 4, 2012
Last verified: June 2012

June 2, 2012
June 4, 2012
August 2012
August 2013   (final data collection date for primary outcome measure)
reduce blood loss during third and fourth stages of labor. [ Time Frame: 1 year ] [ Designated as safety issue: No ]
reduce blood loss during third and fourth stages of labor by using misopristol is better than using oxytocin
Same as current
Complete list of historical versions of study NCT01612390 on ClinicalTrials.gov Archive Site
the duration of the third stage of labor ,need for oxytocics ,blood transfusion and any adverse effects of the drugs [ Time Frame: 1 year ] [ Designated as safety issue: No ]
the duration of the third stage of labor ,needed for oxytocics ,blood transfusion and any adverse effects of the drug will be reduced with mesopristol
Same as current
Not Provided
Not Provided
 
Comparison of Sublingual Misoprostol and Intravenous Oxytocin in Active Management of the Third Stage of Labor
Comparison of Sublingual Misoprostol and Intravenous Oxytocin in Active Management of the Third Stage of Labor

Sublingual misoprostol is superior to oxytocin in reduction of blood loss during the third and fourth stages of labor

Sublingual misoprostol is superior to oxytocin in reduction of blood loss during the third and fourth stages of labor as The data from a pharmacokinetics study suggested that the bioavaiblitiy of misoprostol after sub-lingual administration was higher than those after oral or vaginal administration

Observational
Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

The study will include (180)randomly allocated

Postpartum Hemorrhage Prevention by Using Oxytocin Verses Misoprostol
Not Provided
  • group 1
    receive 400 Mg sublingual misoprostol.
  • group 2
    receive 600 Mg sublingual misoprostol.
  • group 3
    receive 5IU of intravenous oxytocin.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
180
December 2013
August 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Women with aheathy singleton pregnancy in spontaneous or induced labor at term .

Exclusion Criteria:

  • Hypersensitivity/Contraindication to prostaglandins Antepartum hemorrhage Multiple pregnancy Cardiac disease Malpresentation Rhesus- negative mother hypersensitive disorders Severe anaemia(hemoglobin<7g/dl)
Female
18 Years to 40 Years
Yes
Contact: Rasha mohamed, M.B;B.CH abosalma_82@yahoo.com
Egypt
 
NCT01612390
hit 1234
Yes
Rasha Mohammed Mohammed Badawi, Ain Shams University
Rasha Mohammed Mohammed Badawi
Ain Shams University
Principal Investigator: RBadawi mohamed, M.B;B.CH Ain Shams University
Ain Shams University
June 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP